The first-ever adaptive clinical trial for Australians living with MS will seek to reverse neurological damage caused by progressive multiple sclerosis.
Promising developments were announced recently that could significantly elevate the engagement and support people with MS receive from the NDIS.
ATA188, a therapy aiming to retrain T-cells to combat EBV in progressive MS, falls short of expectations. However, the study provides valuable insights in the pursuit of new treatments for MS and highlights MS Australia’s pivotal role in innovative MS research.
MS Australia CEO Rohan Greenland highlights why the upcoming Progress in MS Research Conference will be extra special, including a globally significant announcement, a dedicated focus on the consumer’s voice, and a stellar lineup of international speakers.
An Australian study finds that human herpesvirus 6 (HHV-6) increases the risk of first signs of myelin loss.
The first study of EBV immunity shows reactivation of the virus after AHSCT is not related to relapses in MS.
Researchers find no significant differences in self-reported sleep quality in individuals who use disease-modifying therapies (DMTs).
Challenge yourself with Australia’s most epic charity cycling event, the MS Gong Ride from Sydney to Wollongong and experience the ride of a lifetime while helping fight multiple sclerosis.
A recent study shows that reactive balance training in a controlled environment can be provided to people with MS. Those who receive the training experience improved trip-induced dynamic stability, limb support and trunk control and a reduced number of falls.
